Proactiveinvestors recommends
Additional Information
Market:ASX
Sector:Pharma & Biotech
EPIC:IPD
Latest Price: 0.56  (1.82% Ascending)
52-week High:0.84
52-week Low:0.44
Market Cap:87.52M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
ImpediMed
ImpediMed is a global company with offices in Australia, the USA, and the UK. We develop bioimpedance devices with a focus on medical applications for use in a variety of healthcare segments that are non-invasive, compact and portable, highly accurate, fast, simple to operate, and considerably cheaper than most existing alternatives.

These products have a wide range of potential commercial applications, notably in the assessment and monitoring of secondary lymphedema, general health assessment and weight management, muscle wasting, drug dosing and monitoring and sports medicine and fitness.  The company is pioneering the use of next generation bioimpedance technology both in BIS (Bioimpedance Spectroscopy) and BIA (Bioimpedance Analysis).

ImpediMed L-Dex® technology for breast cancer, CPT code filed with American Medical Assoc.

Thursday, November 12, 2009
ImpediMed L-Dex® technology for breast cancer, CPT code filed with American Medical Assoc.

Queensland-based ImpediMed (ASX: IPD) announced today that an application for a Category 1 Current Procedural Terminology (CPT) Code has been filed with the American Medical Association.

A prominent US based surgeon sponsored the application, which seeks assignment of a dedicated code that can be used by physicians across the US in billing health insurance providers, that use the company’s L-Dex® technology in the prospective management of breast cancer patients at risk of lymphoedema.

ImpediMed CEO Greg Brown said, “we are honoured to have such an accomplished US surgeon sponsor this important milestone in applying for a category one reimbursement code."

ImpediMed plans to drive lymphoedema education and adoption of pre-emptive care for all patients will be greatly enhanced should this code be successful, he said.

In the US, surgeons are the key to facilitating pre-emptive care, their support of a Category 1 code for the L-Dex test, demonstrates a commitment to protecting the quality of life of patients.

The United States CPT coding process is the mechanism by which new technologies are assigned codes, which are used by US public and private health insurance companies to describe the procedures and services offered by clinicians.

The AMA’s CPT Editorial Panel considers and evaluates new coding requests three times each year.

This coding application will be brought in front of the panel during their February 2010 meeting.

ImpediMed is a global leader in developing and distributing medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status.

Investors have saluted the company's progress, pushing the share price up from $0.51 in July, by 47% to the current $0.75.

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.